Adverse Reactions to Thrombolytic Agents

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Medical Toxicology and Adverse Drug Experience

• Publication date

  1987-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF03259869PMID 3306267
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cardiogenic shock complicating acute myocardial infarction.

  1988cited by this paper
• Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction.

  1987cited by this paper
• Role of heparin after intravenous thrombolytic therapy for acute myocardial infarction.

  1987cited by this paper
• Activation of plasminogen by pro-urokinase. I. Mechanism.

  1986cited by this paper
• Identification of patients at risk for anaphylaxis due to streptokinase.

  1986cited by this paper
• Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI).

  1986cited by this paper
• Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction.

  1986cited by this paper
• Activation of Plasminogen by Pro-urokinase

  1986cited by this paper
• Coronary thrombolysis during acute myocardial infarction by intravenous BRL 26921, a new anisoylated plasminogen-streptokinase activator complex.

  1986cited by this paper
• The Systemic Fibrinolytic Effect of BRL 26921 During the Treatment of Acute Peripheral Arterial Occlusions

  1986cited by this paper
• A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days.

  1986cited by this paper
• Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction.

  1986cited by this paper
• Rapid lysis of coronary artery thrombi with anisoylated plasminogen: streptokinase activator complex. Treatment by bolus intravenous injection.

  1986cited by this paper
• Urokinase-related proteins in human urine. Isolation and characterization of single-chain urokinase (pro-urokinase) and urokinase-inhibitor complex.

  1986cited by this paper
• Purification and characterization of recombinant single-chain urokinase produced in Escherichia coli.

  1986cited by this paper
• Ventricular arrhythmias during reperfusion.

  1986cited by this paper
• Pharmacokinetics and Effects on Fibrinolytic and Coagulation Parameters of Two Doses of Recombinant Tissue-Type Plasminogen Activator in Healthy Volunteers

  1986cited by this paper
• Bradycardia and hypotension following reperfusion with streptokinase (Bezold-Jarisch reflex): a sign of coronary thrombolysis and myocardial salvage.

  1986cited by this paper
• Clinical effects and kinetic properties of intravenous APSAC--anisoylated plasminogen-streptokinase activator complex (BRL 26921) in acute myocardial infarction.

  1986cited by this paper
• Intravenous urokinase in acute myocardial infarction.

  1985cited by this paper
• Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator.

  1985cited by this paper
• PRO-UROKINASE - KINETICS AND MECHANISM OF ACTION

  1985cited by this paper
• Immunology of streptokinase in human subjects.

  1985cited by this paper
• The effects of the rate of intravenous infusion of streptokinase and the duration of symptoms on the time interval to reperfusion in patients with acute myocardial infarction.

  1985cited by this paper
• Single-chain urokinase-type plasminogen activators: new hopes for clot-specific lysis.

  1985cited by this paper
• Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials.

  1985cited by this paper
• The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings.

  1985cited by this paper
• Allergic reactions to streptokinase consistent with anaphylactic or antigen-antibody complex-mediated damage.

  1985cited by this paper
• RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION: Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator

  1985cited by this paper
• Intravenous versus intracoronary streptokinase therapy for acute myocardial infarction in community hospitals.

  1984cited by this paper
• Intravenous streptokinase in evolving acute myocardial infarction.

  1984cited by this paper
• A randomized trial of intravenous and intracoronary streptokinase in patients with acute myocardial infarction.

  1984cited by this paper
• Randomized comparison of intravenous versus intracoronary streptokinase for myocardial infarction.

  1984cited by this paper
• Tissue Plasminogen Activator: Chemical and Physiological Aspects

  1984cited by this paper
• Clinical value of intracoronary streptokinase.

  1984cited by this paper
• Streptokinase and the Guillain-Barré syndrome.

  1984cited by this paper
• Clinical failure of streptokinase due to an unsuspected high titer of antistreptokinase antibody.

  1984cited by this paper
• Anaphylactic reactivity to streptokinase.

  1984cited by this paper
• Intracoronary thrombolysis in patients with acute myocardial infarction: comparison of the efficacy of urokinase with streptokinase.

  1984cited by this paper
• Cardiovascular Reflexes Stimulated by Reperfusion of Ischemic Myocardium in Acute Myocardial Infarction

  1983cited by this paper
• Potential electrophysiologic mechanisms responsible for dysrhythmias associated with reperfusion of ischemic myocardium.

  1983cited by this paper
• Factors involved in salvaging ischemic myocardium: effect of reperfusion of arterial blood.

  1983cited by this paper
• Factors involved in salvaging ischemic myocardium: effect of reperfusion of arterial blood.

  1983cited by this paper
• Reperfusion arrhythmia: a marker of restoration of antegrade flow during intracoronary thrombolysis for acute myocardial infarction.

  1983cited by this paper
• Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction.

  1983cited by this paper
• Prospective randomized trial of intravenous and intracoronary streptokinase in acute myocardial infarction.

  1983cited by this paper
• Possible association of Guillain-Barré syndrome with thrombolytic therapy.

  1983cited by this paper
• Coronary reperfusion and Bezold-Jarisch reflex (bradycardia and hypotension).

  1983cited by this paper
• Potential electrophysiologic mechanisms responsible for dysrhythmias associated with reperfusion of ischemic myocardium.

  1983cited by this paper
• Thrombolytic therapy.

  1982cited by this paper
• Local low-dose thrombolytic therapy of peripheral arterial occlusions.

  1982cited by this paper
• Non surgical coronary artery recanalization in acute transmural myocardial infarction.

  1981cited by this paper
• Haemostasis and thrombosis

  1981cited by this paper
• Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy

  1981cited by this paper
• Thrombolytic therapy in thrombosis: a National Institutes of Health consensus development conference.

  1980cited by this paper
• Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction.

  1980cited by this paper
• On the Regulation and Control of Fibrinolysis

  1980cited by this paper
• Acute myocardial infarction: Intracoronary application of nitroglycerin and streptokinase

  1979cited by this paper
• Guidelines for the Use of Thrombolytic Agents

  1979cited by this paper
• Current concepts: guidelines for the use of thrombolytic agents.

  1979cited by this paper
• The use of thrombolytic agents: choice of patient, drug administration, laboratory monitoring.

  1979cited by this paper
• Epidemiology of Guillain-Barré syndrome.

  1978cited by this paper
• Plasminogen activator from human embryonic kidney cell cultures. Evidence for a proactivator.

  1977cited by this paper
• The primary inhibitor of plasmin in human plasma.

  1976cited by this paper
• Purification and characterization of an inhibitor of plasminogen activation from post-traumatic patients

  1976cited by this paper
• Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma.

  1976cited by this paper
• Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis.

  1976cited by this paper
• Molecular Biology of Human Plasminogen

  1975cited by this paper
• A pilot study of streptokinase therapy in acute myocardial infarction: observations on complications and relation to trial design.

  1974cited by this paper
• Urokinase-streptokinase embolism trial. Phase 2 results. A cooperative study.

  1974cited by this paper
• Clinical trials of thrombolytic agents in myocardial infarction.

  1973cited by this paper
• Hypertension. A challenge in preventive cardiology.

  1973cited by this paper
• Fibrinogenolysis and Fibrinolysis with Tissue Plasminogen Activator, Urokinase, Streptokinase-Activated Human Globulin, and Plasmin 1

  1971cited by this paper
• Urokinase pulmonary embolism trial. Phase 1 results: a cooperative study.

  1970cited by this paper
• Streptokinase in iliofemoral venous thrombosis

  1969cited by this paper
• THE DEVELOPMENT OF UROKINASE AS A THROMBOLYTIC AGENT. MAINTENANCE OF A SUSTAINED THROMBOLYTIC STATE IN MAN BY ITS INTRAVENOUS INFUSION.

  1965cited by this paper
• APPRAISAL OF PENICILLINS.

  1963cited by this paper
• Neurological and physiological aspects

  1960cited by this paper
• The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy.

  1958cited by this paper
• A plasminogen activator in spontaneously active human blood.

  1953cited by this paper
• A Plasminogen Activator in Spontaneously Active Human Blood.∗ †

  1953cited by this paper
• Isolation of a Soluble Fibrinolytic Activator from Animal Tissue

  1952cited by this paper
• Pathologic Physiology: Mechanisms of Disease

  1951cited by this paper
• Fibrinolysis in the Animal Organism

  1947cited by this paper
• Observations on fibrinolysis; plasminogen, plasmin, and antiplasmin content of human blood.

  1946cited by this paper
• CLINICAL FEATURES OF SUDDEN OBSTRUCTION OF THE CORONARY ARTERIES

  1912cited by this paper

• Efficacy of Low-Dose Streptokinase Infusion in Late-Onset Permanent Tunnel Catheter Dysfunction: A Single-Center Interventional Study

  2024cites this paper
• Unveiling the Potent Fibrino(geno)lytic, Anticoagulant, and Antithrombotic Effects of Papain, a Cysteine Protease from Carica papaya Latex Using κ-Carrageenan Rat Tail Thrombosis Model

  2023cites this paper
• Regenerative strategies for the consequences of myocardial infarction: Chronological indication and upcoming visions.

  2021cites this paper
• Biomimetic nanoparticle technology for cardiovascular disease detection and treatment.

  2020cites this paper
• Thrombolytic Potential of Novel Thiol-Dependent Fibrinolytic Protease from Bacillus cereus RSA1

  2019cites this paper
• Treating Total Occlusions: Applying Force for Recanalization

  2016cites this paper
• Paramedics beliefs and attitudes towards pre-hospital thrombolysis

  2014cites this paper
• Does the Potential for Development of Streptokinase Antibodies Change the Risk-Benefit Ratio in Older Patients?

  1995cites this paper
• Recent development of rigors during infusion of urokinase: is it related to an endotoxin?

  1994cites this paper
• Renal adverse effects of streptokinase therapy.

  1994cites this paper
• Acute renal failure following intravenous streptokinase infusion for acute myocardial infarction.

  1993cites this paper
• Lack of influence of pretreatment antistreptokinase antibody on efficacy in a multicenter patency comparison of intravenous streptokinase and anistreplase in acute myocardial infarction.

  1992cites this paper
• The pharmacology of aspirin, heparin, coumarin, and thrombolytic agents. Implications for therapeutic use in cardiopulmonary disease.

  1991cites this paper
• Streptokinase-induced jaundice in patients with acute myocardial infarction.

  1991cites this paper
• Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. PRIMI Trial Study Group.

  1989cites this paper